Is the "magic bullet" strategy worth it? While Xeloda works well, it is effective for colorectal tumors and liver cancer. What are the drawbacks for extending this therapy to other types of cancer?
Comment on the effectiveness of targeted prodrugs such as Xeloda for specific cancers such as liver tumors, as well as their effectiveness as a broad "cure for cancer". Compare the "targeted" pro-drug strategy of Xeloda with the "bioavailabity" product strategy of Lexiva.